Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 18/20 | 0.63 |
| ▸ | CTSG | P08311 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2309137 | 0.92 | CMA1 (0.66) | CMA1CTSGMEN1KMT2ASLC22A12 | |
| SCHEMBL2313822 | 0.87 | CMA1 (0.55) | CMA1CTSGMEN1KMT2A | |
| SCHEMBL2313831 | 0.87 | CMA1 (0.55) | CMA1CTSGMEN1KMT2A | |
| SCHEMBL2311173 | 0.87 | CMA1 (0.64) | CMA1CTSG | |
| SCHEMBL2311609 | 0.87 | CMA1 (0.64) | CMA1CTSG | |
| SCHEMBL2313816 | 0.87 | CMA1 (0.64) | CMA1CTSG | |
| SCHEMBL2314906 | 0.86 | CMA1 (0.68) | CMA1CTSGMEN1KMT2ASLC22A12 | |
| SCHEMBL2311205 | 0.84 | CMA1 (0.66) | CMA1CTSGMEN1KMT2ASLC22A12 | |
| SCHEMBL2313675 | 0.84 | CMA1 (0.66) | CMA1CTSGMEN1KMT2ASLC22A12 | |
| SCHEMBL2807565 | 0.84 | CMA1 (0.58) | CMA1CTSGMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | claimed |
| EP-2350030-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council Of Scientific & Industrial Research (IN) | 2011-08-03 | — | — | EP | claimed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | claimed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | claimed |
| WO-2010058417-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-05-27 | — | — | WO | claimed |
| EP-2152674-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-02-17 | — | — | EP | claimed |
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | claimed |
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2152674-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CMA1 1/4885CTSG 26/4885MEN1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.